Rationale for Targeting Androgen Receptor Overexpression in Bladder Cancer
Shilpa Gupta, MD, explains the rationale for adding androgen receptor therapy to cisplatin- and gemcitabine-based chemotherapy.
Shilpa Gupta, MD, associate professor of Genitourinary Oncology at the Cleveland Clinic, explains the rationale for adding androgen receptor (AR) therapy to cisplatin- and gemcitabine-based chemotherapy.
AR is overexpressed in bladder cancer, and preclinical studies have shown that AR is a good target to inhibit when treating patients with bladder cancer. Specifically, AR inhibitors prevent tumor growth and disease progression. There is also research that shows that AR is sensitive to cisplatin, according to Gupta. These early studies served as the rationale for a study in which enzalutamide (Xtandi) was added to cisplatin and gemcitabine.
Aphase I study was conducted with the combination of enzalutamide plus cisplatin and gemcitabine. In the dose-finding portion of the study, patients received either enzalutamide 80mg or 160mg along with the standard doses of cisplatin and gemcitabine.
No dose-limiting toxicities were observed in the dose-finding portion, and the study moved on to the dose-expansion phase.
Need for Systemic Therapy Remains in Sarcoma
November 27th 2023In an interview with Targeted Oncology, Lisa B. Ercolano, MD, discussed the evolving treatment landscape for sarcomas and underscored the pivotal role of molecular profiling, while addressing the need for more efficacious systemic therapies.
Read More
BRUIN MCL-321 Trial Evaluates Pirtobrutinb Monotherapy in MCL
November 20th 2023In an interview with Targeted Oncology, Michael Wang, MD, discussed the rationale of the phase 3 study and how positive results from this trial may further shape the mantle cell lymphoma treatment landscape.
Read More
Neoadjuvant Pembro Plus Chemo Shows EFS Benefit at 5-Years in TNBC
November 13th 2023In an interview with Targeted Oncology, Peter Schmid, FRCP, MD, PhD, discussed the implication of findings from the KEYNOTE-522 trial of the addition of pembrolizumab to neoadjuvant chemotherapy in patients with high-risk triple-negative breast cancer.
Read More
NFBISI-18 Questionnaire Provides QOL Insights in Urothelial Carcinoma
November 13th 2023An analysis, based on data from the JAVELIN 100 Bladder trial, found the NCCN/FACT Bladder Symptom Index-18 for assessing quality-of-life in patients with advanced urothelial carcinoma to be reliable and valid.
Read More
